| Item # | Length | Source of Standard | Year Implemented | Version Implemented | Year Retired | Version Retired |
|---|---|---|---|---|---|---|
| 3,955 | 1 | NAACCR | 2022 | 22 |
This data item stores the Derived Rai stage value derived from the values coded in the following SSDIs for the Lymphoma-CLL/SLL schema (9823/3).
The Rai stage is only applicable for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (9823/3) cases where the primary site is bone marrow (C421). For cases with a primary site other than bone marrow (C421), the derived Rai stage will be 8 and all the SSDIs will be coded to 5.
Derivation will be run on all cases diagnosed 1/1/2018 and forward.
The Derived Rai stage can be used to evaluate disease spread at diagnosis, treatment patterns and outcomes over time.
Codes
| 0 | Lymphocytosis |
| 1 | Lymphocytosis and Adenopathy |
| 2 | Lymphocytosis and Organomegaly (Adenopathy is any value other than 5) |
| 3 | Lymphocytosis and Anemia (Adenopathy and Organomegaly are any value other than 5) |
| 4 | Lymphocytosis and Thrombocytopenia (Adenopathy, Organomegaly and Anemia are any value other than 5) |
| 8 | Does not apply, primary site not bone marrow (C421) (All 5 SSDIs should be set to 5) |
| 9 | Unknown (All 5 SSDIs are 9 or blank; at least one is set to 9 OR Lymphocytosis is 0,7,9 OR Lymphocytosis is blank and one of the other SSDIs is a value other than 5 or 9) |
This field should be left blank for all cases diagnosed prior to 2018, for schemas other than 00795, and when not required by standard setter.